1. Home
  2. Stock quotes
  3. Институт стволовых клеток человека
  4. Financial Statements
  5. Income Statement
Институт стволовых клеток человека logo
Институт стволовых клеток человека ISKJ

Институт стволовых клеток человека Income Statement 2007-2026 | ISKJ

Annual Income Statement Институт стволовых клеток человека

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

Revenue

 1.37 B 1.14 B 1.18 B 1.08 B 836 M 645 M 494 M 390 M 311 M 359 M 420 M 317 M 262 M 193 M 146 M 96.8 M 65.5 M

Cost Of Revenue

 402 M 260 M 290 M 310 M 164 M 79.5 M 92.4 M 67.2 M 47.4 M 29.5 M 16.5 M 32.9 M 28.6 M 2.41 M 4.91 M 1.95 M 415 K

Gross Profit

 966 M 877 M 891 M 774 M 671 M 565 M 402 M 323 M 263 M 330 M 403 M 284 M 233 M 190 M 142 M 94.8 M 65.1 M

Gross Profit Ratio

 0.71 0.77 0.75 0.71 0.8 0.88 0.81 0.83 0.85 0.92 0.96 0.9 0.89 0.99 0.97 0.98 0.99

General and Administrative Expenses

 64.1 M 31.9 M 31.5 M 25.8 M 41.3 M 25.9 M 22.4 M 65.6 M 35.1 M 46.7 M 19.9 M 10.3 M 7.77 M 10.1 M 8.97 M 9.43 M 8.3 M

Selling And Marketing Expenses

 166 M 72.5 M 61.9 M 43.9 M 38.9 M 29.9 M 46.1 M 52.6 M 63.3 M 27.2 M 22.7 M 29.9 M 15.6 M 16.3 M 7.28 M 7.66 M 11.3 M

Selling General And Administrative Expenses

 603 M 104 M 93.3 M 69.7 M 80.2 M 55.8 M 68.5 M 118 M 98.4 M 73.9 M 42.5 M 40.2 M 23.4 M 26.4 M 16.3 M 17.1 M 19.6 M

Other Expenses

 58.1 M 582 M 691 M 557 M 400 M 53.4 M 4.65 M 29.9 M 5.44 M 59.7 M 3.31 M 1.06 M -905 K 144 M 95.6 M 71.3 M 37.3 M

Operating Expenses

 691 M 766 M 795 M 629 M 507 M 515 M 459 M 460 M 358 M 381 M 361 M 314 M 216 M 177 M 114 M 88.6 M 57.3 M

Cost And Expenses

 1.09 B 1.03 B 1.08 B 939 M 672 M 595 M 552 M 527 M 406 M 411 M 378 M 314 M 245 M 180 M 119 M 90.6 M 57.7 M

Interest Expense

 - 67.8 M 50.7 M 40.2 M 41.5 M 30.2 M 30.8 M 27.1 M 8.65 M 11.9 M 18.5 M 5.45 M 414 K 302 K 356 K 215 K 40 K

Depreciation And Amortization

 49.2 M 53.5 M 81.3 M 74.9 M 28.7 M 29.7 M 40.5 M 24 M 26.2 M 25 M 22.5 M 8.99 M 6.07 M 4.99 M 3.56 M 2.22 M 814 K

EBITDA

 326 M 151 M 161 M 209 M 203 M 128 M -2.71 M -98.6 M -58.9 M 37.1 M 64.3 M 10.8 M 25.7 M 15.8 M 53.7 M 11 M 8.89 M

EBITDA Ratio

 0.24 0.13 0.15 0.2 0.25 0.2 -0.01 -0.21 -0.19 0.1 0.15 0.03 0.11 0.11 0.37 0.11 0.14

Operating Income

 276 M 111 M 92.4 M 147 M 181 M 117 M -58.1 M -144 M -95.5 M -51.3 M 42.7 M -11.8 M 16.6 M 7.1 M 27.4 M 6.21 M 7.34 M

Operating Income Ratio

 0.2 0.1 0.08 0.14 0.22 0.18 -0.12 -0.37 -0.31 -0.14 0.1 -0.04 0.06 0.04 0.19 0.06 0.11

Income Before Tax

 211 M 29.3 M 29.5 M 93.5 M 101 M -53.8 M -127 M -150 M -60.3 M 160 K 27.4 M -142 M 19.2 M 9.47 M 50.1 M 8.57 M 8.04 M

Income Before Tax Ratio

 0.15 0.03 0.02 0.09 0.12 -0.08 -0.26 -0.38 -0.19 0.0 0.07 -0.45 0.07 0.05 0.34 0.09 0.12

Income Tax Expense

 16.7 M 6.23 M -4.09 M -9.93 M -9.89 M -35.6 M -17.2 M -18.7 M 2.22 M 16.8 M 10.7 M 7.67 M -1.71 M 3.05 M 5.8 M 1.92 M 2.05 M

Net Income Ratio

 0.12 0.04 0.03 0.1 0.1 -0.05 -0.21 -0.29 -0.17 -0.04 0.04 -0.47 0.07 0.03 0.3 0.07 0.09

Earnings Per Share, EPS

 1.82 0.53 0.42 1.38 1.13 -0.46 -1.37 -1.48 -0.69 -0.18 0.2 -2 2.86 0.12 0.89 0.11 0.1

EPS Diluted

 1.82 0.53 0.42 1.38 1.13 -0.46 -1.37 -1.48 -0.69 -0.18 0.2 -2 2.86 0.12 0.89 0.11 0.1

Weighted Average Shares Outstanding

 92.8 M 86.9 M 80 M 75 M 75 M 75 M 75 M 75 M 75 M 75 M 75 M 75 M 71.5 M 60 M 60.1 M 61.3 M 61.6 M

All numbers in RUB currency

Quarterly Income Statement Институт стволовых клеток человека

2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q1

Revenue

 373 M 373 M 374 M 374 M 311 M 311 M 309 M 309 M 260 M 260 M 624 B 312 M 557 B 278 M 557 B 315 M 631 B 227 M 453 B 225 M 192 M 192 M 176 M 176 M 147 M 147 M 142 M 125 M 112 B 115 B 105 M 82.6 M 109 M 93.6 M 79.4 B 79.4 B 76 M 76 M 92.6 B 92.6 B 87.1 M 106 M 102 M 102 M 121 M

Cost Of Revenue

 93.1 M 93.1 M 119 M 119 M 82.1 M 82.1 M 132 M 132 M 96.5 M 96.5 M 439 B 120 M 404 B 111 M 404 B 161 M 477 B 33.1 M 256 B 62.3 M 39.2 M 39.2 M 26.1 M 26.1 M 35.7 M 35.7 M 39.9 M 12.6 M 31 M 39.8 M 19.8 M 22.2 M 42.9 M 12.7 M 36.5 M 36.5 M 23.7 M 23.7 M 25.2 M 25.2 M 17.8 M 70.6 M 13.5 M 13.5 M 42.6 M

Gross Profit

 280 M 280 M 255 M 255 M 228 M 228 M 176 M 176 M 163 M 163 M 185 B 192 M 153 B 168 M 153 B 154 M 154 B 193 M 197 B 163 M 153 M 153 M 150 M 150 M 111 M 111 M 102 M 113 M 112 B 115 B 85.3 M 60.4 M 66.1 M 81 M 79.4 B 79.4 B 52.3 M 52.3 M 92.6 B 92.6 B 69.3 M 35 M 88.6 M 88.6 M 78 M

Gross Profit Ratio

 0.75 0.75 0.681 0.681 0.736 0.736 0.572 0.572 0.629 0.629 0.296 0.616 0.274 0.602 0.274 0.489 0.244 0.854 0.435 0.724 0.797 0.797 0.852 0.852 0.756 0.756 0.719 0.899 1.0 1.0 0.811 0.731 0.606 0.865 1.0 1.0 0.688 0.688 1.0 1.0 0.796 0.331 0.868 0.868 0.647

General and Administrative Expenses

 17.4 M 17.4 M 20.1 M 20.1 M 12 M 12 M 11 M 11 M 8.66 M 8.66 M - 11.6 M - 7.37 M - 12.6 M - 6.53 M - 16.7 M 9.55 M 9.55 M 9.66 M 9.66 M 6.63 M 6.63 M 3.34 M 2.72 M 10.6 M 10.1 M 9.3 M 19.6 M 15.4 M 20 M 11.3 M 11.3 M 9.38 M 9.38 M 15.8 M 15.8 M 9.72 M 24.3 M 6.53 M 6.53 M 20.9 M

Selling And Marketing Expenses

 52.7 M 52.7 M 39.2 M 39.2 M 43.4 M 43.4 M 34.4 M 34.4 M 22.6 M 22.6 M - 32.6 M - 19.8 M - 24.4 M - 15.6 M - 18 M 11.1 M 11.1 M 5 M 5 M 16.6 M 16.6 M 20.1 M 11.6 M 18.3 M 6.14 M 8.33 M 16.2 M 21.5 M 8.81 M 23.6 M 23.6 M 11.8 M 11.8 M 12 M 12 M 4.33 M 7.47 M 10.7 M 10.7 M 5.7 M

Selling General And Administrative Expenses

 177 M 177 M 149 M 149 M 156 M 156 M 135 M 135 M 117 M 117 M 121 B 134 M 111 B 115 M 111 B 107 M 163 B 98.3 M 101 B 90.1 M 98.5 M 98.5 M 81.5 M 81.5 M 93.8 M 93.8 M 23.4 M 14.3 M 92.4 M 95.6 M 17.6 M 35.8 M 36.9 M 28.8 M 70.2 M 70.2 M 51.1 M 51.1 M 73.2 M 73.2 M 66 M 31.7 M 76.5 M 76.5 M 26.6 M

Other Expenses

 18.8 M 18.8 M 8.67 M 8.67 M 17 M 17 M -19.5 M -19.5 M 11.6 M 11.6 M -278 B 30.4 M -220 B 19 M -212 B 15.5 M -270 B 26.5 M -201 B 15.1 M 18.3 M 18.3 M -6.02 M -6.02 M 17.3 M 17.3 M -5.91 M 6.85 M 5.19 M 10.5 M 28.3 M 4.3 M 5.43 M -8.11 M 3.68 M 3.68 M 2.63 M 2.63 M -3.6 M -3.6 M 8.14 M 70 M 9.91 M 9.91 M -20.6 M

Operating Expenses

 196 M 196 M 169 M 169 M 176 M 176 M 153 M 153 M 132 M 132 M -157 B 165 M -109 B 135 M -101 B 124 M -107 B 125 M -101 B 109 M 117 M 117 M 89.4 M 89.4 M 112 M 112 M 115 M 101 M 100 M 112 M 120 M 138 M 112 M 89.8 M 81.6 M 81.6 M 61.5 M 61.5 M 85.9 M 85.9 M 76.4 M 31.7 M 88.4 M 88.4 M 26.6 M

Cost And Expenses

 289 M 289 M 288 M 288 M 258 M 258 M 285 M 285 M 228 M 228 M 439 B 285 M 404 B 246 M 404 B 285 M 477 B 158 M 256 B 171 M 156 M 156 M 116 M 116 M 148 M 148 M 155 M 114 M 131 M 152 M 140 M 160 M 138 M 89.8 M 118 M 118 M 85.2 M 85.2 M 111 M 111 M 94.2 M 102 M 102 M 102 M 69.2 M

Interest Expense

 - - - - - - - - - - 35.6 B - 28.1 B - 28.1 B - 34 B - 16.2 B - - - - - - - 8.39 M 8.05 M - - 16.7 M 2.84 M 3.9 M 3.64 M - - - - - - - 3.79 M - - 4.49 M

Depreciation And Amortization

 12.8 M 12.8 M 7.96 M 7.96 M 17.1 M 17.1 M 6.89 M 6.89 M 13.1 M 13.1 M 44.5 B 16.2 M 36.8 B 13 M -8.28 B 13.9 M -11.1 B 12.6 M -19.8 B 10.5 M 11.1 M 11.1 M 2.23 M 2.23 M 12.3 M 12.3 M 20.8 M 9.2 M 782 K 9.27 M 5.18 M 7.82 M 4.44 M 6.55 M 6.39 M 6.39 M 5.57 M 5.57 M 5.23 M 5.23 M 6.16 M 71.1 M 6.35 M 6.35 M -19.4 M

EBITDA

 96 M 96 M 96.1 M 96.1 M 67.3 M 67.3 M 33.1 M 33.1 M 40.3 M 40.3 M 72.2 B 48.5 M 80.3 B 45.9 M 43.5 B 44.3 M 36.2 B 81.2 M 76.9 B 64.3 M 47.6 M 47.6 M 62.5 M 62.5 M 10.7 M 10.7 M -55.4 M 32.7 M -18.3 M -27.4 M 3.4 M -49.6 M -58.8 M -4.64 M -32.2 M -32.2 M -3.61 M -3.61 M -11.5 M -11.5 M -961 K 74.4 M 8.46 M 8.46 M 32 M

EBITDA Ratio

 0.258 0.258 0.257 0.257 0.217 0.217 0.107 0.107 0.155 0.155 0.116 0.156 0.144 0.165 0.078 0.14 0.057 0.358 0.17 0.285 0.247 0.247 0.355 0.355 0.073 0.073 0.021 0.232 -0.0 -0.0 0.006 -0.623 -0.54 -0.049 -0.0 -0.0 -0.048 -0.048 -0.0 -0.0 -0.011 0.704 0.083 0.083 0.265

Operating Income

 83.2 M 83.2 M 85.4 M 85.4 M 52.4 M 52.4 M 23.7 M 23.7 M 31.8 M 31.8 M 27.7 B 26.7 M 43.5 B 32.9 M 51.8 B 30.4 M 47.3 B 68.6 M 96.7 B 53.8 M 36.4 M 36.4 M 60.2 M 60.2 M -1.55 M -1.55 M -6.1 M 3.71 M -19.1 M -36.7 M -38.9 M -62.3 M -46.3 M 3.88 M -38.6 M -38.6 M -9.18 M -9.18 M -18.5 M -18.5 M -7.12 M 3.3 M 156 K 156 K 51.4 M

Operating Income Ratio

 0.223 0.223 0.228 0.228 0.169 0.169 0.077 0.077 0.122 0.122 0.044 0.086 0.078 0.118 0.093 0.096 0.075 0.303 0.213 0.239 0.189 0.189 0.343 0.343 -0.011 -0.011 -0.043 0.03 -0.0 -0.0 -0.37 -0.755 -0.425 0.041 -0.0 -0.0 -0.121 -0.121 -0.0 -0.0 -0.082 0.031 0.002 0.002 0.426

Income Before Tax

 50.7 M 50.7 M 84 M 84 M 21.7 M 21.7 M -61 K -61 K 14.7 M 14.7 M 11 B 3.95 M 23.7 B 10.8 M 23.7 B 6.46 M 13.3 B 40.3 M 80.5 B 18.8 M 31.9 M 31.9 M -40.6 M -40.6 M 13.7 M 13.7 M -84.6 M 15.5 M -28.9 M -29.2 M -18.5 M -60.2 M -62.7 M -8.27 M -39 M -39 M 8.82 M 8.82 M -20.8 M -20.8 M 20.9 M 70.6 M -11.7 M -11.7 M 27.5 M

Income Before Tax Ratio

 0.136 0.136 0.225 0.225 0.07 0.07 -0.0 -0.0 0.057 0.057 0.018 0.013 0.043 0.039 0.043 0.02 0.021 0.178 0.178 0.083 0.166 0.166 -0.231 -0.231 0.093 0.093 -0.595 0.124 -0.0 -0.0 -0.176 -0.73 -0.575 -0.088 -0.0 -0.0 0.116 0.116 -0.0 -0.0 0.24 0.668 -0.115 -0.115 0.228

Income Tax Expense

 1.14 M 1.14 M 4.68 M 4.68 M 3.68 M 3.68 M 3.36 M 3.36 M 249 K 249 K 200 M 100 K -4.29 B 2.14 B -4.29 B 898 K 1.8 B 5.86 B -11.7 B 5.47 B 528 K 528 K 14.6 M 14.6 M 3.21 B 3.21 B -5.65 M -9.68 M 2.16 M 282 K -6.26 M -11.9 M 403 K -1 M 778 K 778 K 1.89 M 1.89 M 2.49 M 2.49 M 5.89 M 16.6 M 2.04 M 2.04 M 6.4 M

Net Income Ratio

 0.112 0.112 0.183 0.183 0.051 0.051 0.034 0.034 0.048 0.048 0.017 -0.013 0.05 0.035 0.05 0.001 0.018 0.16 0.204 0.074 0.133 0.133 -0.192 -0.192 0.113 0.113 -0.585 0.198 -0.0 -0.0 -0.06 -0.506 -0.514 -0.078 -0.0 -0.0 0.108 0.108 -0.0 -0.0 0.192 0.511 -0.128 -0.128 0.175

Earnings Per Share, EPS

 0.001 0.001 0.001 0.001 0.0 0.0 0.0 0.0 0.0 0.0 0.15 - 0.38 0.0 0.38 - 0.16 0.001 1.23 K 0.0 0.0 0.0 -0.0 -0.0 0.0 0.0 -1.11 0.33 -0.0 -0.0 -0.084 -0.56 -0.75 -0.097 -0.001 -0.001 0.0 0.0 -0.0 -0.0 0.0 0.72 -0.0 -0.0 0.28

EPS Diluted

 0.001 0.001 0.001 0.001 0.0 0.0 0.0 0.0 0.0 0.0 0.15 - 0.38 0.0 0.38 - 0.16 0.001 1.23 K 0.0 0.0 0.0 -0.0 -0.0 0.0 0.0 -1.11 0.33 -0.0 -0.0 -0.084 -0.56 -0.75 -0.097 -0.001 -0.001 0.0 0.0 -0.0 -0.0 0.0 0.72 -0.0 -0.0 0.28

Weighted Average Shares Outstanding

 73.9 B 73.9 B 75.3 B 75.3 B 74.2 B 74.2 B 88.8 B 88.8 B 86.3 B 86.3 B 73.4 B 85 B 72.8 B 75.8 B 72.8 B 75 B 72.8 B 75 B 75 M 75 B 75.5 B 75.5 B 75 B 75 B 75 B 75 B 75 M 75 M 75 B 75 B 75 M 75 M - 75 M 75 B 75 B 75 B 75 B 75 B 75 B 75 B 75 M 75 B 75 B 75 M

All numbers in RUB currency

The income statement is one of the three key financial reports of a company Институт стволовых клеток человека (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
 		- 2.43 % $ 254 M germanyGermany
Aligos Therapeutics Aligos Therapeutics
ALGS
 		$ 8.64 8.07 % $ 85.4 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
 		$ 3.66 -1.48 % $ 8.81 B australiaAustralia
I-Mab I-Mab
IMAB
 		- - $ 866 M chinaChina
AlloVir AlloVir
ALVR
 		- 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
 		- - $ 10.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
 		- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
 		- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
 		- -13.47 % $ 169 M franceFrance
Applied Therapeutics Applied Therapeutics
APLT
 		- - $ 8.42 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
 		- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
 		- -18.52 % $ 27.3 M britainBritain
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
 		$ 21.36 4.86 % $ 998 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
 		- -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
 		- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
 		- -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
 		- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
 		- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
 		- - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
 		$ 1.47 5.0 % $ 378 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
 		- - $ 26.5 M usaUSA
Allakos Allakos
ALLK
 		- - $ 28.6 M usaUSA
Aptinyx Aptinyx
APTX
 		- -39.0 % $ 4.57 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
 		$ 2.92 - $ 4.81 M israelIsrael
Aquestive Therapeutics Aquestive Therapeutics
AQST
 		$ 4.19 2.7 % $ 448 M usaUSA
Aravive Aravive
ARAV
 		- -13.39 % $ 1.45 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
 		$ 24.12 -0.37 % $ 3.07 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
 		- 1.93 % $ 17.4 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
 		$ 32.59 1.09 % $ 2.16 B usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
 		$ 1.47 -1.34 % $ 391 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
 		- -45.71 % $ 1.2 M canadaCanada
Cidara Therapeutics Cidara Therapeutics
CDTX
 		- - $ 1.41 B usaUSA
AVROBIO AVROBIO
AVRO
 		- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
 		- - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
 		- - $ 96.9 B britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
 		- - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
 		- - $ 867 M germanyGermany
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
 		- -2.5 % $ 5.88 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
 		- 0.49 % $ 251 B cayman-islandsCayman-islands
Akouos Akouos
AKUS
 		- 0.23 % $ 488 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
 		$ 4.25 8.35 % $ 286 B britainBritain
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
 		- 3.16 % $ 1.9 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
 		$ 2.22 2.3 % $ 461 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
 		$ 0.82 1.13 % $ 27.9 M israelIsrael
Baudax Bio Baudax Bio
BXRX
 		- 0.59 % $ 63 K usaUSA
Cabaletta Bio Cabaletta Bio
CABA
 		$ 3.2 2.24 % $ 322 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
 		- - $ 2.17 B usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
 		- - $ 3.45 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
 		- 10.36 % $ 9.8 M usaUSA